Immix Biopharma is under investigation by Block & Leviton for potential securities fraud after it was revealed that an executive using the name Richard Graydon was actually a fugitive operating under a false identity. The company fired the individual, stating his short tenure had no material impact on the business. Following the news, Immix shares fell about 10.83%. Block & Leviton is exploring legal actions to help investors recover losses and encourages affected shareholders to contact them for assistance.
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share transactions on August 7, 2026. The bank purchased 9,541 ordinary shares at 281.25 per share and sold 147,431 shares between 281 and 28...
Berkshire Hathaway reported a $1.8 billion increase in operating earnings last quarter, with a significant $1.2 billion portion attributed to favorable currency exchange movements. This currency impact notably boosted the company's financial results,...
The global Travel Now Pay Later (TNPL) market, valued at $45 billion in 2024, is projected to reach $77.6 billion by 2030, growing at a 9.5% CAGR. TNPL allows travelers to book flights, hotels, and tours with flexible installment payments, boosting b...
Jyske Realkredit A/S has published preliminary data regarding early redemptions (prepayments) of its issued bonds, dated August 7, 2026. This disclosure complies with the Capital Markets Act and provides investors with updated information on bond pre...
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
